<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185415</url>
  </required_header>
  <id_info>
    <org_study_id>PSP003</org_study_id>
    <secondary_id>2019-002377-61</secondary_id>
    <nct_id>NCT04185415</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)</brief_title>
  <official_title>A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and tolerability of UCB0107 in study&#xD;
      participants with Progressive Supranuclear Palsy (PSP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs) from Baseline to the last Visit</measure>
    <time_frame>From Baseline up to Week 68</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>bepranemab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive bepranemab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bepranemab</intervention_name>
    <description>bepranemab will be administered in a predefined dosage.&#xD;
Pharmaceutical Form: Solution for infusion&#xD;
Route of Administration: Intravenous</description>
    <arm_group_label>bepranemab</arm_group_label>
    <other_name>UCB0107</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical Form: Solution for infusion&#xD;
Concentration: 0.9% w/v sodium chloride aqueous solution&#xD;
Route of Administration: Intravenous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be ≥40 years of age at the time of signing the informed consent&#xD;
&#xD;
          -  Participants meet the criteria for possible or probable Progressive Supranuclear Palsy&#xD;
             (PSP) Richardson's Syndrome according the Movement Disorder Society (MDS)-PSP criteria&#xD;
&#xD;
          -  Participant is able to walk at least 5 steps with minimal or no assistance&#xD;
             (stabilization of one arm or use of cane/walker)&#xD;
&#xD;
          -  Participant has reliable caregiver support during the whole study period or the&#xD;
             participant is able to independently follow the study protocol&#xD;
&#xD;
          -  Participant is stable on all treatments for at least 2 weeks prior to the Baseline&#xD;
             Visit&#xD;
&#xD;
          -  Participant has a body mass index (BMI) within the range 16.0 to 32.0 kg/m^2&#xD;
             (inclusive)&#xD;
&#xD;
          -  Participants can be male or female&#xD;
&#xD;
          -  Participant (and caregiver or legal representative, if applicable) is capable of&#xD;
             giving signed informed consent which includes compliance with the requirements and&#xD;
             restrictions listed in the Informed Consent form (ICF) and in this protocol. Informed&#xD;
             consent must be obtained before initiating any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing, recurrent, severe headaches, including migraines&#xD;
&#xD;
          -  Evidence of any clinically significant neurological disorder (including any clinically&#xD;
             significant abnormalities on the screening magnetic resonance imaging) other than&#xD;
             Progressive Supranuclear Palsy (PSP)&#xD;
&#xD;
          -  Participant has a lifetime history of suicide attempt, or has suicidal ideation with&#xD;
             at least some intent to act in the past 12 months as indicated by a positive response&#xD;
             (&quot;Yes&quot;) to either Question 4 or Question 5 of the &quot;Screening/Baseline&quot; version of the&#xD;
             Columbia-suicide severity rating scale (C-SSRS) at Screening&#xD;
&#xD;
          -  Sensitivity to any of the study interventions, or components thereof, or drug or other&#xD;
             allergy that, in the opinion of the Investigator or medical monitor, contraindicates&#xD;
             participation in the study&#xD;
&#xD;
          -  The following liver enzyme test results:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline&#xD;
                  phosphatase (ALP) are &gt;2.0x upper limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin &gt;1.5x ULN (isolated bilirubin &gt;1.5x ULN is acceptable if bilirubin is&#xD;
                  fractionated and direct bilirubin is &lt;35 %)&#xD;
&#xD;
          -  The mean QT interval value (corrected by Fredericia's formula for the heart rate,&#xD;
             QTcF) of the 3 Screening ECGs is &gt;450 msec for male participants or &gt;470 msec for&#xD;
             female participants or QTcF is &gt;480 msec in participants with bundle branch block&#xD;
&#xD;
          -  Abnormalities in lumbar spine previously known or determined by a Screening lumbar&#xD;
             x-ray (if conducted) that may jeopardize the execution of the lumbar puncture&#xD;
&#xD;
          -  Participant was previously treated with tau-protein targeting drugs and/or tau-protein&#xD;
             targeting antibodies or vaccines.&#xD;
&#xD;
          -  Treatment with biologic agents (such as monoclonal antibodies including marketed&#xD;
             drugs) within 3 months or 5 half-lives (whichever is longer) prior to the first dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psp003 40122</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40002</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40277</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40276</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40278</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40024</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40159</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40267</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40100</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40268</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40166</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40175</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp003 40165</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive Supranuclear Palsy</keyword>
  <keyword>UCB0107</keyword>
  <keyword>Phase 1 study</keyword>
  <keyword>PSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

